Talquetamab + teclistamab in patients with triple-class exposed R/R MM and EMD: The RedirecTT-1 study Talquetamab + teclistamab in patients with triple-class exposed R/R MM and EMD: The RedirecTT-1 study June 2025 Congress News Read more
2023 November Clinical trials Decitabine monotherapy: A safer alternative to chemotherapy for older patients with AML Read more
2023 September Clinical trials Reduced annualised bleeding rate in haemophilia patients receiving concizumab Read more
2023 August Clinical trials Dasatinib with intensive chemotherapy is safe and effective in paediatric Ph-positive ALL Read more
Top
